



Basic Virological Aspects of SARS-CoV-2

Guest Editors:

Dr. Andreu Comas-Garcia

Dr. Sofia Bernal-Silva

Prof. Dr. S. Louise Cosby

Deadline for manuscript
submissions:

closed (31 December 2023)

Message from the Guest Editors

This new information required about SARS-CoV-2 needed to be focused on understanding the physiopathology of the COVID-19 disease, identifying biomarkers, and designing a vaccine and treatments. The scope of this Special Issue is to gather information about the basic virology aspects of SARS-CoV-2 and their impact on the design of vaccines and/or drugs. Further, the basic virology aspect can be focused on to understand the physiopathology of COVID-19 disease.

Before the COVID-19 pandemic, SARS viruses had a relative slow evolution rate. However, globalization, unequal strategies to control or mitigate the pandemic around the world, and the generation of several vaccines increased the evolution rate. This evolution, centered in the scape of the immune system, had a great impact on the persistence of the pandemic and a critical decrease in vaccines' effectiveness. Therefore, understanding the basic virological aspect of this virus through high-quality information will allow us to generate better strategies against this virus.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com